Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and ...

Wa'el Hashad Wa'el Hashad, Chief Executive Officer, Longeveron Inc. Pivotal Phase 2b clinical trial (ELPIS II) evaluating ...

The FDA granted priority review to TLX250-CDx for clear cell renal cell carcinoma imaging, with a PDUFA date of August 27, ...

The FDA granted RMAT designation to nogapendekin alfa and CAR-NK for reversing lymphopenia in patients with cancer, with ...

Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...

An international student has displayed the messages a man in his 40s sent her on WhatsApp because she rejected him. The messages got many people talking.

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Outlook Therapeutics (OTLK) announced it has re-submitted its Biologics License Application, BLA, to the U.S. Food and Drug Administration, ...

Precigen's PRGN-2012 and UltraCAR-Ts offer groundbreaking therapies. Read why PGEN stock is a strong pick, with major ...

Organogenesis ( ORGO -5.54%) Q4 2024 Earnings Call Feb 27, 2025, 5:00 p.m. ET ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

After a second round, the U.S. FDA has accepted for review radiopharmaceutical company Telix Pharmaceuticals Ltd.’s BLA for ...